Speakers

Expand/Collapse

Alejandro Rangel
Associate Professor of Medicine
Universidad Panamericana

Day 2 afternoon

12:00 pm | Panel Discussion: Integrating Biomarkers Throughout the Trajectory of CNS Drug Discovery & Development to Guide Clinical Decisions

Andrea Crotti
Principal Scientist - Early Discovery
Takeda

Ashley Barnes
Chief Scientific Officer
Axol Bio

Track A - Day 2

11:00 am | Differentiated iPSC Co-Culture Model Development for Neurodegenerative Diseases

Beth Hoffman
Founder, President & Chief Executive Officer
Origami Therapeutics

Day 2 afternoon

4:00 pm | Exploring CNS Application of Protein Degraders to Determine Whether They Can be Utilized in a Selective Manner to Minimize Side Effects & Maximize Therapeutic Outcome

Carlos Pedraza
Director – Central Nervous System & Biology
Alkermes

Chan Tan
Principal Scientist
BridgeBio Pharma

Track B - Day 2

10:45 am |
Upgrading Your Therapeutic Approach Against Alzheimer’s & Parkinson’s

Chris Winrow
Vice President & Head of Translational Medicine
Cyclerion

Day 2 afternoon

12:00 pm | Panel Discussion: Integrating Biomarkers Throughout the Trajectory of CNS Drug Discovery & Development to Guide Clinical Decisions

Track B - Day 1 PM

2:30 pm | From Concept to Clinic: Targeting the Nitric Oxide-Soluble Guanylate Cyclase-cGMP Pathway for Neurodegenerative Diseases

Cory Nicholas
Chief Executive Officer
NeuronaTx

Day 2 afternoon

5:00 pm | Uncovering Targeted Neural Cell Therapies for Chronic Disorders of the Nervous System

Craig Shering
Global Product Leader
AstraZeneca

Day One

9:00 am | Exploring Big Pharma’s Direction in Neurodegenerative Disease

Daniel Alkon
President –Research
Synaptogenix

Track B - Day 1 PM

2:00 pm | Uncovering Bryostatin Targets Restoration of Synaptic Wiring Lost in Alzheimer’s Degeneration

David Bearss
President and CEO
Halia Therapeutics

Day Two

9:00 am | Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer’s

Dimitry Ofengeim
Head of Precision Neurology & Neuroinflammation
Sanofi

Pre-Conference Discussion Day

Monday, March 28, 2022

8:02 am | Defining Approaches for Precision Neurology

Eric Nelson
Senior Business Development Consultant
US HealthVest

Track A - Day 1 PM

1:14 pm |
Streamlining Target Discovery

Track B - Day 1 AM

11:03 am |
Analyzing the Latest Biomarkers Research to Determine Which One is the Most Useful for Neurodegenerative Disease Drug Development

George Tetz
Chief Executive Officer
CLS Therapeutics & The Human Microbiology Institute

Track A - Day 2

11:30 am | Uncovering Microbiome-Derived Therapeutic Targets to Treat Alzheimer’s Disease

Gergely Toth
Chief Executive Officer & Chief Scientific Officer
Cantabio

Graham Dempsey
Chief Scientific, Officer
Q-State Bio

Pre-Conference Discussion Day

Monday, March 28, 2022

1:03 pm | Investigating Therapeutic Discovery Platforms for Oligonucleotides Targeting Neurodegenerative Diseases

Habib Baghirov
Senior Scientific, Business Analyst
Roche

Pre-Conference Discussion Day

Monday, March 28, 2022

8:03 am | Utilizing Innovative Delivery Technology to Move Across the Blood Brain Barrier & Optimize Precision Targeting of Neurons

James Koprich
Chief Technology Officer
Atuka

Day Two

9:30 am | Update on Animal Models of Alpha-Synucleinopathy for Use in Therapeutic Drug Development

Jamil Beg
Life Science, Venture Capitalist, & Entrepreneur
5am Ventures

Day 2 afternoon

3:00 pm | Panel Discussion: The New Landscape in NDD investing: How the 2021 Events Have Changed Outlooks

Jay Barth
Executive Vice President & Chief, Medical Officer
Lexeo Therapeutics

Track B - Day 2

11:00 am | Discovering Gene therapy for APOE4-Associated Alzheimer’s Disease

Je Min Yoo
Chief Technology Officer
BioGraphene Inc

Track A - Day 1 PM

2:30 pm | The New Target Journey: How to Progress from Target Identification & Illustrate Meaningful Effect in Pre-Clinical Models

Johanna Withers
Vice President, Clinical Development and Operations
Scipher Medicine

Day Two

10:00 am | Precision Medicine Driven by the SPECTRA Network Biology Platform in Neurodegenerative Disorders

Johannes Krupp
Research Program Director for Neurology
Servier

Day 2 afternoon

2:30 pm | Showcasing LRRK2 Inhibitors as Treatment for Parkinson’s Disease

John Gustofson
Managing Director
AbbVie

Day 2 afternoon

3:00 pm | Panel Discussion: The New Landscape in NDD investing: How the 2021 Events Have Changed Outlooks

John Hey
Chief Scientific Officer
Alzheon

Track B - Day 1 AM

12:30 pm | Fluid & Imaging Biomarkers in ALZ-801 Development: A First-in-Class Oral Disease Modifying Agent for Alzheimer’s Disease

Jonathan Behr
Partner
Dementia Discovery Fund

Day 2 afternoon

3:00 pm | Panel Discussion: The New Landscape in NDD investing: How the 2021 Events Have Changed Outlooks

Jonathan Proto
Principal Scientist
Sanofi

Track A - Day 1 PM

2:00 pm | Learning How to Integrate Information on Cellular Communication & Pathways for a Multi-Omic Approach to Target Identification

Katherine Deng
Principal Scientist
AbbVie

Track A - Day 1 AM

11:50 am | In Vitro Transcytosis Models for BBB targeting CNS Drug Screening

Keechan Ahn
Chief Scientific Officer
Astrogen

Lisa Shafer
Chief Scientific Officer
Cerebral Therapeutics

Day 2 afternoon

2:00 pm | Analyzing Translational Approaches for Brain Targeted Drug Delivery

Magdalene Moran
President & Chief Scientific Officer
Carraway Therapeutics

Day 2 afternoon

12:00 pm | Panel Discussion: Integrating Biomarkers Throughout the Trajectory of CNS Drug Discovery & Development to Guide Clinical Decisions

Track B - Day 2

11:30 am | Enhancing Lysosomal Function as a Therapeutic Strategy for Parkinson’s Disease

Manuel Sanchez-Felix
Senior Fellow, Novel Delivery Technologies
Novartis

Track B - Day 1 PM

1:14 pm |
Analyzing Key Clinical Trial Updates

Marcia Taylor
Vice President of Research
Treventis

Track A - Day 1 AM

11:20 am | Discovery of Small Molecule Dual Inhibitors of Abeta and tau Aggregation using CCM technology

Margaret Magdesian
Chief Executive Officer & Founder
Ananda Devices

Track A - Day 1 AM

12:20 pm | High Throughput Platform for Rapid Screening of Compounds on Over 3 000 Patients’ Derived Neurons in 30 Minutes

Maria Usenovic
Associate Principal Scientist
Merck

Day One

9:00 am | Exploring Big Pharma’s Direction in Neurodegenerative Disease

Mark Kiel, MD, PhD
Chief Scientific Officer
Genomenon

Track B - Day 1 AM

1:00 pm | An AI-Driven Locus-Specific Database (LSDB) for 35 ALS-Associated Genes

Martin Tolar
Founder, President & Chief Executive Officer
Alzheon

Day One

4:00 pm | ALZ-801 Phase 3 Program: Lessons & The Path Forward in Developing Targeted Therapies for Alzheimer’s Disease

Melissa Geddie
Principal Scientist – Antibody Discovery
Biogen

Michela Gallagher
Founder & Chief Executive Officer
Agene Bio

Mitesh Parekh
Account Manager
bit.bio

Track A - Day 1 AM

12:30 pm | Advancing Neurodegenerative Drug Discovery with a New Class of Consistent, Scalable Human iPSCDerived cells

Murali Gopalakrishnan
Global Head of Neuroscience Search & Evaluation
AbbVie

Day One

9:00 am | Exploring Big Pharma’s Direction in Neurodegenerative Disease

8:55 am | Chair’s Opening Remarks

Day Two

8:55 am | Chair’s Opening Remarks

Neil Cashman
Chief Scientific Officer & Co-Founder
ProMIS Neurosciences

Track A - Day 1 PM

3:00 pm | Abeta oligomers in Alzheimer Disease: Target Engagement and Target Distraction

Patrick Sarmiere
Senior Director of Molecular Pharmacology
Ovid Therapeutics

Day 2 afternoon

5:30 pm | RNA interference (RNAi) Approaches for Allele Specific, Gain of Function Mutations in Rare, Monogenic Neurodevelopmental Disorders

Track A - Day 2

10:56 am |
Zoning in on Neurodegenerative Disease Targets

Phllip Kong
Associate Director for Translational Medicine
Alector

Track A - Day 1 AM

11:03 am |
Closing the Translational Gap: Update on Neurodegenerative Disease Models & Imaging

Piet van der Graaf
Senior Vice President, Quantitative Systems Pharmacology
Certara

Day One

9:30 am | How Regulatory-Ready Biosimulation is Revolutionizing Neurodegenerative Drug Development

Raj Ganesan
Senior Director -Protein Engineering & Antibody Discovery Research
Alector

Raphael Lis
Assistant Professor in Regenerative & Reproductive Medicine & Director of the Starr Foundation Stem Cell Derivation Laboratory
Weill Cornell Medicine

Rob Shaffer
Founder
Enable Therapeutics

Pre-Conference Discussion Day

Monday, March 28, 2022

1:03 pm | Targeting Glycogen in Childhood Dementia with Expansion Potential to Larger Neurodegenerative Indications

Ross Jeggo
Global Head of Neuroscience & Immuno-Inflammation Therapeutic Aria
Servier

Pre-Conference Discussion Day

Monday, March 28, 2022

1:02 pm | Exploring RNA Targeted Approaches for Rare Movement Disorders

Sam Henderson
Chief Scientific Officer
Cerecin

Day 2 afternoon

4:30 pm | Metabolic Dysfunction in Neurodegenerative Disorders: Spotlight on Parkinson’s, Huntington’s & Alzheimer’s

Sharon Rosenzweig-Lipson
Vice President of Research & Development
AgeneBio

Track B - Day 1 AM

11:20 am | How to Define Patient Selection, Selection of Optimal Intervention Points & Therapeutic Outcomes Using Biomarkers & “Prodromal AD”

Stan Chamberlain
Chief Scientific Officer
T3D Therapeutics

Day One

4:30 pm | Deep Diving into the Development of a PPAR Delta/Gamma Agonist T3D-959 for Alzheimer’s Disease

Steve Smith
Director of Business Development
GemPharmatech

Track B - Day 1 AM

11:50 am | Novel GEM Models For Exploring Neurodegenerative Disease Therapeutics